ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate profile

ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate

Cross-References

ID Source	ID
PubMed CID	54217
CHEMBL ID	14093
SCHEMBL ID	4731655
MeSH ID	M0104853

Synonyms (27)

Synonym
b-80706
clomoxir ethyl
b-80727
cpoc
poca
ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate
ethyl 2-(5-(4-chlorophenyl)pentyl)oxirane-2-carboxylate
glycidic acid, 2-(5-(p-chlorophenyl)pentyl)-, ethyl ester
2-(5-(p-chlorophenyl)pentyl)glycidic acid ethyl ester
2-(5-(4-chlorophenyl)pentyl)oxiranecarboxylic acid ethyl ester
oxiranecarboxylic acid, 2-(5-(4-chlorophenyl)pentyl)-, ethyl ester
b 807-06
oxirane-2-carboxylic acid, 2-(5-(p-chlorophenyl)pentyl)-, ethyl ester
CHEMBL14093
ethyl 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate
unii-87xb8j7fll
78573-55-4
87xb8j7fll ,
DNORZUSMZSZZKU-UHFFFAOYSA-N
2-[5-(4-chlorophenyl)pentyl]oxirane 2-carboxylic acid ethyl ester
SCHEMBL4731655
wy-49422
2-oxiranecarboxylic acid, 2-(5-(4-chlorophenyl)pentyl)-, ethyl ester
ethyl-2(5(4-chlorophenyl)pentyl)oxiran-2-carboxylate
Q27269857
DTXSID80999847
PD127719

Bioassays (7)

Assay ID	Title	Year	Journal	Article
AID719774	Reduction in blood glucose in po dosed Sprague-Dawley rat	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID70216	Tested for its effect on hepatic epoxide hydrolase; No significant inhibition up to 1e-3 mol/L	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Synthesis and hypoglycemic activity of phenylalkyloxiranecarboxylic acid derivatives.
AID719775	Reduction in blood glucose in Sprague-Dawley rat at 600 umol/kg, po	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID116917	Compound was tested for its lethality in mice when administered perorally	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Synthesis and hypoglycemic activity of phenylalkyloxiranecarboxylic acid derivatives.
AID177862	Effective dose at which 50% of the rats show at least a 25% decrease of blood glucose levels compared to controls	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Synthesis and hypoglycemic activity of phenylalkyloxiranecarboxylic acid derivatives.
AID719773	Toxicity in po dosed Sprague-Dawley rat assessed as hypoglycemic coma	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
AID176120	Ability to decrease blood glucose levels in fasted rats at the dose of 0.6 mmol/kg was determined	1982	Journal of medicinal chemistry, Feb, Volume: 25, Issue:2	Synthesis and hypoglycemic activity of phenylalkyloxiranecarboxylic acid derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	23 (53.49)	18.7374
1990's	14 (32.56)	18.2507
2000's	1 (2.33)	29.6817
2010's	3 (6.98)	24.3611
2020's	2 (4.65)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.17%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	45 (97.83%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Description	Relationhip Strength	Studies	Classes	Roles
b 807-27	[no description available]	medium	4
4-hydroxyphenylglyoxylic acid	[no description available]	medium	1	phenols
2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylic acid	[no description available]	medium	1
amiodarone	[no description available]	medium	1	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
perhexiline	[no description available]	medium	1	piperidines	cardiovascular drug
trimetazidine	[no description available]	medium	1	aromatic amine
4-hydroxyphenylglycine, (s)-isomer	[no description available]	medium	1	4-hydroxyphenylglycine
methyl 2-tetradecylglycidate	[no description available]	medium	1
emeriamine	[no description available]	medium	1
etomoxir	[no description available]	medium	1	aromatic ether
4-trimethylammonio-3-((tetradecylcarbamoyl)amino)butyrate	[no description available]	medium	1
4-methylene-2-octyl-5-oxofuran-3-carboxylic acid	[no description available]	medium	1	4-methylidene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid; gamma-lactone
lactic acid	[no description available]	medium	6	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
fluorodeoxyglucose f18	[no description available]	medium	1	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
5,6,7-trimethoxyflavone	[no description available]	medium	1	trimethoxyflavone	anti-HSV-1 agent; plant metabolite
glucagon	[no description available]	medium	1	peptide hormone
4-pentenoic acid	[no description available]	medium	1	pentenoic acid
valproic acid	[no description available]	medium	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
oleic acid	[no description available]	medium	1	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
octanoic acid	[no description available]	medium	1	medium-chain fatty acid; straight-chain saturated fatty acid	antibacterial agent; Escherichia coli metabolite; human metabolite
caprylates	[no description available]	medium	2	fatty acid anion 8:0; straight-chain saturated fatty acid anion	human metabolite; Saccharomyces cerevisiae metabolite
succinic acid	[no description available]	medium	1	alpha,omega-dicarboxylic acid; C4-dicarboxylic acid	anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent
palmitoyl coenzyme a	[no description available]	medium	1	11,12-saturated fatty acyl-CoA; 3-substituted propionyl-CoA; long-chain fatty acyl-CoA; palmitoyl bioconjugate	Escherichia coli metabolite; mouse metabolite
carnitine	[no description available]	medium	8	amino-acid betaine	human metabolite; mouse metabolite
styrene oxide	[no description available]	medium	1	epoxide	human xenobiotic metabolite
acetylcarnitine	[no description available]	medium	1	O-acylcarnitine	human metabolite
glycine	[no description available]	medium	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
4-hydroxyphenylglycine	[no description available]	medium	1	hydroxy-amino acid	bacterial metabolite
ferric chloride	[no description available]	medium	1	iron coordination entity	astringent; Lewis acid
iohexol	[no description available]	medium	1	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
phytanic acid	[no description available]	medium	2	branched-chain saturated fatty acid; long-chain fatty acid; methyl-branched fatty acid
palmitic acid	[no description available]	medium	3	long-chain fatty acid; straight-chain saturated fatty acid	algal metabolite; Daphnia magna metabolite; EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor; plant metabolite
lignoceric acid	[no description available]	medium	1	straight-chain saturated fatty acid; very long-chain fatty acid	Daphnia tenebrosa metabolite; human metabolite; plant metabolite; volatile oil component
chlorine	[no description available]	medium	1	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
masoprocol	[no description available]	medium	1	nordihydroguaiaretic acid	antineoplastic agent; hypoglycemic agent; lipoxygenase inhibitor; metabolite
indomethacin	[no description available]	medium	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
arachidonic acid	[no description available]	medium	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
pyruvic acid	[no description available]	medium	3	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
pristanic acid	[no description available]	medium	1	branched-chain saturated fatty acid; long-chain fatty acid; methyl-branched fatty acid	human metabolite
hexacosanoic acid	[no description available]	medium	1	fatty acid 26:0; straight-chain saturated fatty acid; very long-chain fatty acid
14-fluoro-6-thiaheptadecanoic acid	[no description available]	medium	1
citric acid, anhydrous	[no description available]	medium	1	tricarboxylic acid	antimicrobial agent; chelator; food acidity regulator; fundamental metabolite
acetyl coenzyme a	[no description available]	medium	1	acyl-CoA	acyl donor; coenzyme; effector; fundamental metabolite
sucrose	[no description available]	medium	1	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
omega-(4-iodophenyl)pentadecanoic acid	[no description available]	medium	1
palmitoylcarnitine	[no description available]	medium	2	O-palmitoylcarnitine; saturated fatty acyl-L-carnitine	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; human metabolite; mouse metabolite
phosphocreatine	[no description available]	medium	1	phosphagen; phosphoamino acid	human metabolite; mouse metabolite
prazosin	[no description available]	medium	1	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
lysophosphatidylcholines	[no description available]	medium	1	1-O-acyl-sn-glycero-3-phosphocholine
clofibric acid	[no description available]	medium	1	aromatic ether; monocarboxylic acid; monochlorobenzenes	anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist
coenzyme a	[no description available]	medium	1	adenosine 3',5'-bisphosphate	coenzyme; Escherichia coli metabolite; mouse metabolite
clofibrate	[no description available]	medium	1	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
ciprofibrate	[no description available]	medium	1	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
2-tetradecylglycidic acid	[no description available]	medium	2
chlorpromazine	[no description available]	medium	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
glycerol	[no description available]	medium	2	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
bezafibrate	[no description available]	medium	1	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
2-bromopalmitate	[no description available]	medium	1	2-bromocarboxylic acid; bromo fatty acid; long-chain fatty acid; straight-chain fatty acid	fatty acid oxidation inhibitor
2-bromooctanoic acid	[no description available]	medium	1

Condition	Relationship Strength	Studies
Addison Disease and Cerebral Sclerosis	low	3
Adrenoleukodystrophy	low	3
Adrenomyeloneuropathy	low	3
ALD (Adrenoleukodystrophy)	low	3
Alloxan Diabetes	low	2
Anoxemia	low	2
Anoxia	low	2
Astrocytoma, Grade IV	low	1
Body Weight	low	1
Bronze Schilder Disease	low	3
Canine Diseases	low	1
Cardiac Failure	low	1
Cardiac Hypertrophy	low	1
Cardiomegaly	low	1
Cardiovascular Stroke	low	1
Cat Diseases	low	1
Cerebro-Hepato-Renal Syndrome	low	3
Cerebrohepatorenal Syndrome	low	3
Chondrodysplasia Punctata	low	1
Chondrodysplasia Punctata 2, X-Linked	low	1
Chondrodysplasia Punctata 2, X-Linked Dominant	low	1
Chondrodystrophia Calcificans Congenita	low	1
Congestive Heart Failure	low	1
Conradi Hunermann Happle Syndrome	low	1
Conradi-Hu00FCnermann Syndrome	low	1
Conradi-Hu00FCnermann-Happle Syndrome	low	1
Conradi-Hunermann Syndrome	low	1
Conradi-Hunermann-Happle Syndrome	low	1
Coronary Disease	low	3
Coronary Heart Disease	low	3
Deficiency, Oxygen	low	2
Deficiency, Riboflavin	low	1
Diabetes Mellitus	low	1
Diabetes Mellitus, Adult-Onset	low	1
Diabetes Mellitus, Experimental	low	2
Diabetes Mellitus, Ketosis-Resistant	low	1
Diabetes Mellitus, Maturity-Onset	low	1
Diabetes Mellitus, Non Insulin Dependent	low	1
Diabetes Mellitus, Non-Insulin-Dependent	low	1
Diabetes Mellitus, Noninsulin Dependent	low	1
Diabetes Mellitus, Noninsulin-Dependent	low	1
Diabetes Mellitus, Slow-Onset	low	1
Diabetes Mellitus, Stable	low	1
Diabetes Mellitus, Type 2	low	1
Diabetes Mellitus, Type II	low	1
Disease Models, Animal	low	2
Dog Diseases	low	1
Dysplasia Epiphysialis Punctata	low	1
Enlarged Heart	low	1
Epiphyses, Stippled	low	1
Experimental Diabetes Mellitus	low	2
Feline Diseases	low	1
Giant Cell Glioblastoma	low	1
Glioblastoma	low	1
Glioblastoma Multiforme	low	1
Happle Syndrome	low	1
Heart Attack	low	1
Heart Decompensation	low	1
Heart Disease, Ischemic	low	3
Heart Enlargement	low	1
Heart Failure	low	1
Heart Failure, Congestive	low	1
Heart Failure, Left-Sided	low	1
Heart Failure, Right-Sided	low	1
Heart Hypertrophy	low	1
Hunermann-Conradi Syndrome	low	1
Hypoxemia	low	2
Hypoxia	low	2
Inborn Errors of Metabolism	low	1
Injury, Myocardial Reperfusion	low	1
Insulin Resistance	low	3
Insulin Sensitivity	low	3
Ischemia, Myocardial	low	3
Ischemic Heart Disease	low	3
Left-Sided Heart Failure	low	1
Maturity-Onset Diabetes	low	1
Maturity-Onset Diabetes Mellitus	low	1
Melanodermic Leukodystrophy	low	3
Metabolism Errors, Inborn	low	1
Metabolism, Inborn Errors	low	1
MODY	low	1
Muscle Contraction	low	1
Myocardial Failure	low	1
Myocardial Infarct	low	1
Myocardial Infarction	low	1
Myocardial Ischemia	low	3
Myocardial Ischemic Reperfusion Injury	low	1
Myocardial Reperfusion Injury	low	1
NIDDM	low	1
Noninsulin-Dependent Diabetes Mellitus	low	1
Obesity	low	2
Oxygen Deficiency	low	2
PBD, ZSS	low	3
Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum	low	3
Reperfusion Injury, Myocardial	low	1
Riboflavin Deficiency	low	1
Right-Sided Heart Failure	low	1
Schilder-Addison Complex	low	3
Sensitivity and Specificity	low	1
Siemerling-Creutzfeldt Disease	low	3
Starvation	low	1
Stippled Epiphyses	low	1
Streptozocin Diabetes	low	2
Streptozotocin Diabetes	low	2
Type 2 Diabetes	low	1
Type 2 Diabetes Mellitus	low	1
Ventricular Fibrillation	low	2
X-ALD	low	3
X-ALD (X-Linked Adrenoleukodystrophy)	low	3
X-Linked Adrenoleukodystrophy	low	3
X-Linked Chondrodysplasia Punctata 2	low	1
X-Linked Dominant Chondrodysplasia Punctata	low	1
Zellweger Disease	low	3
Zellweger Spectrum	low	3
Zellweger Syndrome	low	3
Zellweger Syndrome Spectrum	low	3
Zellweger-Like Syndrome	low	3
Zellweger's Syndrome	low	3

Research Highlights

Long-term Use (1)

Article	Year
Metabolic changes in fed rats caused by chronic administration of ethyl 2[5(4-chlorophenyl)pentyl]oxirane-2-carboxylate, a new hypoglycaemic compound. Biochemical pharmacology, Feb-01, Volume: 33, Issue: 3	1984
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

ethyl 2-(5-(4-chlorophenyl)pentyl)oxiran-2-carboxylate

Cross-References

Synonyms (27)

Bioassays (7)

Research

Studies (43)

Study Types

Related Drugs (59)

Related Conditions (118)

Research Highlights

Long-term Use (1)